A comprehensive view of Epidemic / Pandemic. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Moderna announces Phase 3 success of next-gen COVID-19 vaccine, forthcoming flu combo vaccine, and progress in pivotal viral caccines set for 2024
Published:
March 28, 2024
by Industry Intelligence Inc.
|
Moderna initiates final phase of trials for four vaccines against latent infections, including chickenpox and shingles, and norovirus responsible for gastroenteritis; the company also developing a new-generation COVID-19 vaccine
Published:
March 27, 2024
by CE Noticias Financieras (Latin America)
|
US restaurant traffic sees 1% year-over-year growth in 2023, and the industry now stands at US$500B, with dollars exceeding 2019 levels by 12%, despite traffic remaining 8% below pre-pandemic levels: Circana
Published:
March 27, 2024
by Targeted News Service (Press Releases)
|
Moderna's next-generation COVID-19 vaccine, mRNA-1283, shows a higher immune response against SARS-CoV-2 in Phase 3 trial compared to the company's currently vaccine; the new vaccine also has potential for longer shelf life and storage benefits
Published:
March 26, 2024
by Moderna Inc.
|
BioNTech receives a notice of default from the NIH over allegedly owed vaccine royalties under a prior licensing agreement
Published:
March 25, 2024
by FiercePharma
|
Ask us about our Health Care Sector market view